| Literature DB >> 30232554 |
M J van Son1, M T W T Lock2, M Peters3, E E Fransen van de Putte4, R P Meijer2.
Abstract
PURPOSE: To compare open surgical anastomotic revision with endourological techniques for the treatment of ureteroenteric strictures in patients with urinary diversions.Entities:
Keywords: Anastomosis; Endoscopy; Re-implantation; Stenosis; Urinary diversion
Mesh:
Year: 2018 PMID: 30232554 PMCID: PMC6533231 DOI: 10.1007/s00345-018-2475-4
Source DB: PubMed Journal: World J Urol ISSN: 0724-4983 Impact factor: 4.226
Baseline characteristics of the study population
| No. of patients (%) | |
|---|---|
| Overall | 76/88 renal units |
| Sex | |
| Male | 48 (63) |
| Female | 28 (37) |
| Mean age at urinary diversion in years | 56 (SD 15.6) |
| Mean BMI at urinary diversion (range) | 26 (19.4–33.8) |
| Reasons for urinary diversion | |
| Cancer | 49 (65) |
| Severe incontinence | 10 (13) |
| Radiation cystitis | 7 (9) |
| Neurogenic bladder disorder | 4 (5) |
| Bladder exstrophy | 3 (4) |
| Interstitial cystitis | 1 (1) |
| Unknown | 2 (3) |
| Diversion type | |
| Ileal conduit | 62 (82) |
| Indiana pouch | 9 (12) |
| Orthotopic neobladder | 4 (5) |
| Colon conduit | 1 (1) |
| Stricture side per patient | |
| Left | 35 (46) |
| Right | 29 (38) |
| Bilateral | 12 (16) |
| Stricture presentation per UES | |
| Asymptomatic | 44 (27) |
| Flank pain and/or infection | 61 (38) |
| Unknown | 56 (35) |
| Median interval from cystectomy to diagnosis of UES in months (range) | 31 (0.5–573) |
BMI body mass index, UES ureteroenteric stricture
Characteristics of the study population at start of treatment
| Total procedures | Endo | Open | ||
|---|---|---|---|---|
| Mean age at treatment: years (range) | 63 (28–84) | 63.2 | 60.1 | 0.326 |
| Mean BMI at treatment | 25.9 | 25.4 | 27.4 | 0.099 |
| ASA score at treatment | ||||
| I–II | 66 (41) | 53 (39) | 13 (50) | 0.279 |
| III–IV | 94 (58) | 81 (60) | 13 (50) | |
| V–VI | 0 (0) | 0 (0) | 0 (0) | |
| Unknown | 1 (1) | 1 (1) | 0 (0) | |
| Stricture side | ||||
| Left | 88 (55) | 73 (54) | 15 (58) | 0.734 |
| Right | 73 (45) | 62 (46) | 11 (42) | |
| Stricture length | ||||
| < 1 cm | 5 (3) | 5 (3) | 0 (0) | 0.999 |
| > 1 cm | 33 (21) | 28 (21) | 5 (19) | |
| Unknown | 123 (76) | 102 (76) | 21 (81) | |
| History of pelvic radiotherapy | 42 (26) | 36 (27) | 6 (23) | 0.703 |
| History of chemotherapya | 15 (9) | 13 (10) | 2 (8) | 0.999 |
| Primary procedure | ||||
| Yes | 86 (53) | 72 (53) | 14 (54) | 0.962 |
| No | 75 (47) | 63 (47) | 12 (46) | |
| Mean renal function of affected renal unit on renogram | 53.1% | 53.9% | 49.8% | 0.557 |
| Mean interval from diagnosis to treatment, in months | 3.1 | 2.8 | 4.6 | 0.142 |
BMI body mass index, ASA American Society of Anesthesiologists
aNeoadjuvant or adjuvant to cystectomy
Treatment results of endourological vs. open surgical approach
| Endo ( | Open ( | ||
|---|---|---|---|
| Absolute patency rate | 37.8% | 69.2% | 0.003 |
| Wallstent ( | 42.2% | ||
| Laser ( | 26.7% | ||
| Balloon ( | 36.4% | ||
| Absolute patency rate primary procedures | 38.9% | 64.3% | 0.079 |
| Median patency duration in months (range) | 5 (1 days-256 months) | 15.5 (10 days-242 months) | 0.014 |
| Number of Clavien–Dindo complications ≤ 30 days | |||
| 1 | 1 (1%) | 0 | |
| 2 | 5 (4%) | 7 (27%) | |
| 3a | 2 (1.5%) | 0 | |
| 3b | 2 (1.5%) | 2 (8%) | 0.528 |
| 4 | 0 | 1 (4%) | |
| 5 | 0 | 0 | |
| Median hospital stay in days (range) | 2 (0–10) | 14 (3–40) | < 0.001 |
| Mean eGFRa improvement (range) | + 8.1 (− 3.9 + 74.4) | +17.0 (− 8.0 + 36.0) | 0.024 |
eGFR estimated glomerular filtration rate
aCalculated with MDRD formula in mL/min/1.73 m2
Fig. 1a Kaplan–Meier analysis for stricture-free survival after primary procedures. b Kaplan–Meier analysis for stricture-free survival after all procedures
Multivariable Cox proportional hazards regression analysis
| HR (95% CI) | ||
|---|---|---|
| Treatment type | 0.36 (0.17–0.74) | 0.006 |
| + Age | 0.36 (0.17–0.75) | 0.006 |
| + ASA score | 0.36 (0.17–0.75) | 0.006 |
| + Body mass index | 0.34 (0.16–0.74) | 0.006 |
| + History of chemotherapy | 0.35 (0.16–0.75) | 0.007 |
| + History of pelvic radiotherapy | 0.34 (0.16–0.73) | 0.006 |
| + Kidney function | 0.35 (0.16–0.76) | 0.008 |
| + Stricture side | 0.35 (0.16–0.77) | 0.009 |
| + Primary procedure | 0.35 (0.16–0.77) | 0.009 |
HR hazard ratio, 95% CI 95% confidence interval, ASA American Society of Anesthesiologists score